Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT02086994 |
| Other study ID # |
khalid77 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
Phase 3
|
| First received |
March 5, 2014 |
| Last updated |
February 13, 2017 |
| Start date |
March 2013 |
| Est. completion date |
August 2015 |
Study information
| Verified date |
February 2017 |
| Source |
Benha University |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
We aim to compare carbetocin with misoprostol for the prevention of postpartum hemorrhage in
patients with severe preeclampsia. The primary outcome is postpartum haemorrhage (blood loss
of ≥ 500 ml) while our Secondary outcomes include use of additional uterotonics, need for
blood transfusion, maternal adverse drug reaction, maternal complications and maternal death
Description:
We conducted a prospective non-randomized study at Department of Obstetrics and Gynecology,
Benha University Hospital, since March 2013 till June 2015, after approval of the study
protocol by the Local Ethical Committee. A written informed consent was obtained from
eligible women before induction or at early stage of labour.
Women with singleton pregnancies of more than 28 weeks' gestation who are admitted to
hospital with severe preeclampsia and candidates for vaginal delivery were eligible for the
study. Preeclampsia is labelled as severe in the presence of any of the following
abnormalities.
1. Persistent cerebral or visual disturbances or cerebral edema.
2. Persistent epigastric pain with nausea or vomiting, or both.
3. Systolic ≥160 mmHg or diastolic ≥110 mmHg on 2 occasions at least 6 h apart with the
patient at bed rest.
4. Proteinuria of ≥5 g on 24-hour urine collection. Urine dipsticks are not accurate for
this purpose.
5. Oliguria (˂500 mL in 24 hours).
6. Pulmonary edema.
7. Thrombocytopenia.
Our exclusion criteria are HELLP syndrome, eclampsia, abruptio placentae, malpresentation,
polyhydramnios, previous uterine scar, chorioamnionitis and multiple pregnancies. All
patients were in stable condition (no evidence of maternal hemodynamic instability or fetal
distress) and their management afterwards followed the standards accepted in our country and
established guidelines for the management of hypertensive disorders of pregnancy. For
hypertensive crisis the first drug used was hydralazine (5 mg IV every 15 minutes to a
maximum total dose of 20 mg) and, if this was ineffective, Nifedipine (Epilat): 10 to 20 mg
orally / 30 min (max 50 mg), Then 10-20 mg /4-6 h (max 120 mg/day) or labetalol (20 mg IV
every 10 minutes to a maximum total dose of 300 mg). No patient needed additional treatment
for their symptoms or developed antepartum complications that required admission to the
intensive care unit. All patients were evaluated hourly and received magnesium sulphate to
prevent eclampsia during the pregnancy and for a minimum of 24 hours postpartum.
The patients (60) were divided into two groups, Group A (30) received a single dose of
carbetocin (100 μg in 1 mL ampoule, Pabal) while Group B (30) received misoprostol (600 μg,
3 tables) sublingually after the delivery of the anterior shoulder of the baby.
The third stage of labour is managed as usual by clamping and cutting of umbilical cord,
waiting for signs of placental separation and delivering the placenta by controlled cord
traction.
Duration of the 3rd stage of labour is calculated. Patient is kept in labor room under
observation for a period of 1 h and any complaint such as nausea, vomiting, fever, headache,
chills, diarrhoea and shivering is noted. In cases of uterine atony (determined by physical
examination and continuous postpartum bleeding) uterus is massaged and additional
uterotonics were given and noted (oxytocin and/or prostaglandin, at the discretion of the
attending physician). Any requirement for manual removal of the placenta or blood
transfusion is also recorded.
The following laboratory assessments (hemoglobin, hematocrit, platelets, and renal and liver
function tests) are performed in every patient on admission and postpartum. Vital signs
(blood pressure, heart rate, respiratory rate) and urine output are measured every hour
until at least 24 hours after delivery.
Measurement of blood loss A clean plastic lined absorbent drape is placed under the woman's
buttocks to collect all the blood lost after delivery of the baby and drainage of the
amniotic fluid. The drape is changed as many times as needed. The woman stays on the drape
or asked to wear a pad over the next 60 minutes. In the case of severe haemorrhage, we
follow the usual guidelines for management of postpartum haemorrhage, and the supplemental
treatment is registered. All drapes and pads are weighed on an electronic scale and the
known dry weight of the linen is subtracted. As 1 ml of blood weighs close to 1 g, the
balance in grams is assumed to be the total blood loss in ml.
Haemoglobin concentration is measured before, 2 hours and 24 hours after delivery.
The rate of haemorrhage at labour third phase is determined by observation estimation
considering the amount of blood under the patient. The rate of haemoglobin and haematocrit
are measured at hospitalization and also 2 h, 24 h after delivery and then are recorded. At
this interval, the patients are evaluated in terms of possible complications of administered
drugs such as vomiting, diarrhoea, shivering, pyrexia, and headache).
All patients have the Foley catheter in situ for 24 hours after delivery and the amount of
urine was monitored hourly.
This study has no external funding source. No author had any potential relationships that
may pose conflict of interest.
Outcome measures Our primary outcome measure is postpartum haemorrhage, defined as a blood
loss of ≥ 500 ml. We analyse the blood loss, change in haemoglobin concentration between
admission and discharge. While secondary outcomes include use of additional uterotonics,
need for blood transfusion, maternal adverse drug reaction (such as headache, vomiting,
abdominal pain, pruritus, tacky or bradycardia), sever maternal complications (such as
seizures or need for ICU admission) and maternal death.
